Here’s a concise overview of the main patent milestones around insulin, from discovery to the modern era.
- Discovery and early patenting (1920s)
- 1921: Frederick Banting and Charles Best, at the University of Toronto, discovered how to extract and purify insulin to treat diabetes (with key purification work by James Collip).
- 1922–1923: Patents were filed in Canada and the United States covering insulin purification and its therapeutic use. The University of Toronto held the core patent rights and assigned them to the university itself.
- Licensing to industry: The University of Toronto licensed the insulin patents to commercial manufacturers, most famously Eli Lilly in the United States, to enable large-scale production. It is commonly described as a nominal payment (often cited as a token amount such as $1) with royalties to the university, though exact terms varied by region and time.
- Growth of industrial production (1920s–1950s)
- Eli Lilly and other companies rapidly produced and commercialized insulin (including animal-sourced forms like porcine and bovine insulin) to meet growing medical demand.
- These early insulin products were protected by patents and trade secrets related to purification, formulation, and manufacturing processes. Over time, many of the original patents expired, allowing broader generic-like competition for older insulin formulations.
- Structural understanding and non-patent milestones (1950s onward)
- 1950s–1960s: Fundamental biochemical work (including amino acid sequencing of insulin) and refinements in purification improved product consistency, but these scientific milestones were not all patent-focused. They did, however, influence subsequent biotechnological approaches and new product development.
- Recombinant DNA insulin (biosynthetic insulin) era (1980s–present)
- 1982: The first recombinant human insulin (Humulin) was approved (in the U.S.). It was produced by Genentech using recombinant DNA technology and marketed by Eli Lilly. This marked a shift from animal-sourced insulin to biosynthetic human insulin.
- This era introduced a new wave of patents covering recombinant DNA methods, specific production strains, purification methods, and the exact sequences used to make human insulin in microorganisms.
- 1980s–2000s: Many insulin analogs were developed and patented, each with its own patent portfolio. Notable examples (with approximate dates) include:
- Insulin lispro (Humalog) – late 1980s to 1990s
- Insulin aspart (Novolog) – early 1990s
- Insulin glargine (Lantus) – around 2000
- Insulin detemir (Levemir) – mid-2000s
- Insulin degludec (Tresiba) – 2010s
- These analogs typically carried their own sets of patents governing the amino acid substitutions, manufacturing processes, and formulation technologies. Many of these patents have expired or are expiring, while some newer formulations or delivery technologies may still be protected in particular jurisdictions.
- Current landscape
- Old, animal-derived insulin products (porcine/bovine) are broadly off-patent in most markets; those products are widely available as generics or through competition.
- Brand-name insulin analogs and newer delivery technologies continue to be protected by patents and regulatory exclusivities in many markets, though patent expiry timelines vary by country.
- Biosimilars (follow-on versions of recombinant human insulin and some analogs) have entered many markets since the 2010s, adding contracting competition even as individual product patents persist.
If you want more detail, I can:
- Provide country-by-country patent timelines (US, Europe, Canada, etc.) with approximate grant dates and known patent numbers.
- List key patent numbers for specific insulin products (e.g., Humulin, Humalog, Novolog, Lantus, Levemir, Tresiba) and their expiry ranges.
- Point you to primary sources (patent databases like USPTO, Google Patents, Espacenet, WIPO) for in-depth research.